Clinical Trial Update: Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A Patients [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating low-dose emicizumab compared with low-dose Factor VIII for prophylaxis in Hemophilia A patients. The study is currently no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Factor VIII (Factor VIII)
• Hemlibra (emicizumab)

Snippet

Sponsor: Dhaka Medical College | Conditions: Hemophilia A | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING